Project description
A novel skincare laser against hyperpigmentation
Birthmarks and pigmentation disorders such as melasma or freckles may be distressing for many people. Skin examination and often biopsy are undertaken to exclude the possibility of melanoma. Hyperpigmentation is treated using various methods such as light or laser therapy, which target the affected area. The EU-funded LIGHTSENSE project is introducing a non-thermal ablative laser to improve skincare and advance hyperpigmentation treatment. Initially developed for removing tattoos, the LIGHTSENSE technology is now also aimed at many skin conditions. The project is supporting a feasibility study for validating the technological performance of the new laser, accompanied by commercial and financial strategy planning.
Objective
LightSense Technologies has developed and patented an innovative, non thermal ablative laser which constitutes a leap forward in laser technology with the potential to dramatically improve laser skincare and position Europe as a leader in medical and aesthetic applications. We are initially focused on tattoo removal because (1) the market is very large and growing, and well defined with clear patient needs, (2) the competitive offering is terrible, and (3) we have already developed meaningful intellectual property in this specific application with approved patents to support our work. We intend to quickly expand beyond tattoo removal, establishing industry-wide and academically-recognized laser solutions for many dermatology applications. We will begin by validating our business plan through the implementation of a Feasibility Study. The study will aim to better understand (A) technology performance in different laser-skin tissue studies, (B) commercial research with key stakeholders, and (C) financial strategy definition, as explained below. With this information, we will improve our laser tattoo removal treatment and refine our go-to- market strategy. LightSense Technologies forecasts ~€30M in revenues by 2021 (~€800M by 2030). Projections take in consideration an average price of € 2,850 per treatment, assuming a decrease thereafter.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
- medical and health sciencesclinical medicinedermatology
- social scienceseconomics and businessbusiness and managementbusiness models
- natural sciencesphysical sciencesopticslaser physics
You need to log in or register to use this function
Programme(s)
Funding Scheme
SME-1 - SME instrument phase 1Coordinator
N12 0BP London
United Kingdom
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.